Nielsen Barbara Rubek, Jørgensen Niklas Rye, Schwarz Peter
Department of Geriatrics, Research Centre of Ageing and Osteoporosis, Glostrup University Hospital, University of Copenhagen, DK-2650 Glostrup, Denmark.
J Asthma. 2008 Aug;45(6):519-22. doi: 10.1080/02770900802085469.
To investigate the extent of inhaled glucocorticoid (IGC) treatment in general and to what extent general practitioners (GPs) manage the risk of glucocorticoid-induced osteoporosis.
A questionnaire was sent to all 3,617 GPs in Denmark.
The results are divided into criteria for recommending prophylaxis with calcium and vitamin D for patients in actual IGC treatment, routine examinations for osteoporosis before starting asthma or chronic obstructive pulmonary disease (COPD) treatment with IGC, and criteria for starting anti-osteoporotic treatment (bisphosphonates + calcium + vitamin D) for patients in IGC treatment. A total of 535 questionnaires were eligible for evaluation and covered almost 25% of the Danish population. In general, the questionnaires documented that physicians do not use primary nor secondary prophylaxis in their patients treated with IGC with or without risk factors of osteoporosis.
More studies are warranted to verify the effects of IGC treatment on bone health and the importance of prophylaxis to prevent osteoporosis in IGC-treated patients before outlining specific recommendations for the management of the disease.
调查吸入性糖皮质激素（IGC）治疗的总体情况，以及全科医生（GP）对糖皮质激素诱导骨质疏松症风险的管理程度。
向丹麦所有3617名全科医生发送了一份问卷。
结果分为针对实际接受IGC治疗患者推荐钙和维生素D预防的标准、在开始使用IGC治疗哮喘或慢性阻塞性肺疾病（COPD）之前进行骨质疏松症常规检查的标准，以及针对接受IGC治疗患者开始抗骨质疏松治疗（双膦酸盐+钙+维生素D）的标准。共有535份问卷符合评估条件，覆盖了近25%的丹麦人口。总体而言，问卷表明医生在接受IGC治疗的患者中，无论有无骨质疏松风险因素，都未采用一级或二级预防措施。
在概述该疾病管理的具体建议之前，需要更多研究来验证IGC治疗对骨骼健康的影响以及预防IGC治疗患者骨质疏松症的重要性。
